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CHAPTER 1 - INTRODUCTION
1.1 Ovarian cancer and the issue of missing heritability
Ovarian cancer (OVCA) is the eleventh most common cancer amongst
women and the fifth leading cause of cancer related deaths, with a five year
survival rate of less than 50%(“Ovarian Cancer - Cancer Stat Facts,” 2018).
According to the National Cancer Institute (NCI), since 1992 there has been a
progressive decrease in the number of new cases of ovarian cancer, so prevention
efforts have made an impact. However, this trend does not stand as strongly for
the number of deaths due to OVCA. OVCA is a rare form of cancer and the number
of deaths from this disease has not changed in recent years. It is still ranked among
the top 10 cancers in lethality attributed to its poor survival. The five year survival
from 1992 – 2009 was 49.2% and remains almost the same in 2019.
The different types of cancers of ovarian cancer are referred to by the cell
type from they are derived from epithelial, germ cell and stromal. In addition, the
subtype classification, pathologic grade, histology, are factors in prognosis and
treatment (Torre et al., 2018). Epithelial ovarian cancer (EOC) can be classified
histologically as serous, mucinous or clear cell. Additionally, EOC can be
categorized as type I or II. Type I is considered to be a low-grade carcinoma with
a higher survival rate and more associated with somatic mutations. In comparison,
Type II EOC is more aggressive with a lower survival due to the spreading of the
cancer cells beyond the ovaries, often with late-stage diagnosis (Torre et al.,
2018). Less aggressive ovarian malignancies include non-epithelial ovarian
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cancers encompassing germ cell, stromal tumors, small cell carcinoma and
ovarian sarcoma.
Approximately 25% of all EOC cases are considered to be hereditary but
this figure is most likely an underestimation due to missing heritability (Bodmer &
Tomlinson, 2010; Manolio et al., 2009). BRCA1 and BRCA2 are tumor suppressor
genes and account for 5 – 10% of all OVCA cases (Ramus & Gayther, 2009).
Hereditary EOC is part of the hereditary breast and ovarian cancer syndrome,
which has an autosomal dominant inheritance pattern. Patients with a genetic
predisposition of EOC are characterized by one or more of the following: family
history of ovarian and/or breast cancer, Ashkenazi Jewish heritage, early age of
onset, presence of BRCA1/2 mutations, and mutations in other DNA repair genes
or mutated mismatch repair genes associated with Lynch syndrome (Saslow et al.,
2012). Current EOC patients that fit one or more of these classifications are
recommended to undergo genetic testing of buccal or blood DNA. The panel for
risk assessment of HBOC consists of 25 genes involved in DNA repair, cell cycle
regulation, cell adhesion, RAS signaling, and enzymatic activity. The panel is a
comprehensive testing tool for cancers including the breast, ovarian and uterine
(Figure 1). However, panel testing is limited to the assessment for mutations
already implemented in disease risk. This process does not allow for the discovery
of novel risk mutations in panel genes or in genes that are part of the same
pathway or have a similar function. Whole genome or exome sequencing (WES)
of patient blood and/or tumor DNA is required to identify germline variants that are
not among these panel genes. Using the genome analysis toolkit (GATK), a
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pipeline optimized for accuracy and performance of next generation sequencing
(NGS) analysis, variants of interest are identified based on the American College
of Medical Genetics (ACMG) guidelines. While the progression of panel testing for
genetic heritability of rare diseases and disorders has grown in the past decade,
determining the genetic risk of disease is still complex.
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Figure 1: Risk genes associated with ovarian, breast and uterine carcinomas
modified from Ambry Genetics
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EOC individuals who have been diagnosed or are suspected to be at risk of
the disease are recommended to undergo testing of their germline DNA for known
pathogenic mutations in 25 ovarian and breast cancer associated genes (Figure
1). Germline DNA is sequenced using next generation sequencing (NGS)
technology and the raw data is processed and formatted to a variant call format
(VCF) text file that stores gene sequences. In the case of germline variants, criteria
to identify mutations of interest include low minor allele frequency, type of mutation,
location of mutation, segregation data, evidence of cancer risk association in
publically available databases that report on the relationships of human variation
and phenotypes, genotype to phenotype literary evidence, algorithms that predict
the impact of the variant, and conservation scores. All variants of interest are
confirmed by Sanger sequencing to ensure that false positives are not reported as
disease-causing. Clinical geneticists use the molecular genetic profiles to highlight
the most significant findings to the patient including important variants found in the
associated gene(s), the evidence used to interpret variant, and relevance of the
findings to both the patient and family members.
1.2 Variant Classification
Guidelines have been created by the American College of Medical Genetics
(ACMG) to determine variant classification (Richards et al., 2015a). Variants can
be classified into five groups; pathogenic, likely pathogenic, unknown significance,
benign or likely benign. Pathogenic or likely pathogenic variants are sub-classified
as very strong, strong, moderate or supporting based on evidence for the particular
mutation (Table 1) (Richards et al., 2015a). Benign variants can also be sub-
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classified as stand-alone, strong or supporting (Richards et al., 2015b). There are
several different types of data that determines if a variant is pathogenic or benign.
Population, computational, functional, segregation, de novo, allelic, other
databases, population data, computational and functional data determines a
mutations impact (Table 1) (Richards et al., 2015b). The purpose of benign subclassification is to ensure that the variant does not impact protein function and
overall patient risk. Variants of unknown significance (VUS) are classified as such
if there is conflicting evidence of the mutation being pathogenic or benign. The
mutation may be novel, private or there is opposing evidence of its impact on
protein function (Amendola et al., 2016; Richards et al., 2015a).
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Classification

Benign

SubClassification

Strong

Population
data

X

Computational
and predictive
data

Pathogenic

Supporting

X

Supporting

X

Functional
data

X

X

Segregation
data

X

X

De novo data

Moderate

Strong

X

X

X

X

Very
Strong

X

X
X

X
X

Allelic data

X

Other
databases

X

X

Other data

X

X

Table 1: American College of Medical Genetics guidelines for variant
classification (modified).
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1.3 Variants of unknown significance impacts missing heritability
A primary contributor to the issue of missing heritability is variants of
unknown significance (VUS) (Bodmer & Tomlinson, 2010). The mutations effect
on protein function and the patient is not known (Richards et al., 2015b). Often,
patients are made aware of a VUS after genetic testing. But they cannot be
counseled due to the lack of information about the impact of the mutation on protein
function (Richards et al., 2015b). Essentially there is a gap of knowledge that does
not allow clinicians to counsel patients on their true genetic risk. An important step
in evaluating the significance of a genetic lesion is to use a combination of
computational and laboratory techniques. It has been proposed that instead of high
throughput sequencing of a set of panel genes, whole genome (WGS) or whole
exome sequencing (WES) is a more powerful method of assessing patients who
are suspected to have a hereditary risk of cancer (Chaudhry, Stafford, Tainsky, &
Levin, 2017). Clinicians can gain a better understanding of the genetic profile of
patients, identify novel risk loci outside of the standard genetic panels and have
the ability to re-visit the data (Chaudhry et al., 2017). The guidelines for variant
assessment is constantly being updated by both National Comprehensive Cancer
Network (NCCN) (Pilarski et al., 2018) and ACMG (Richards et al., 2015b).
Therefore, reassessing WES/WGS patient data will ease the financial and
resource burden of resequencing and data processing.
1.4 The limitations of genome wide association (GWAS) studies
A large portion of individual differences in disease susceptibility is due to
genetic factors. Identifying and characterizing novel variants gives a personalized
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approach to the prevention, diagnosis, and treatment of disease (Manolio et al.,
2009). A previous source of promise was conducting GWAS to identify pathogenic
mutations from thousands of affected and/or unaffected individuals. Due to the
rarity of OVCA, the frequency of the germline variants in the general population is
quite low, but most allele thresholds for GWAS studies at least 5% of the population
(Auer & Lettre, 2015). GWAS explains a small fraction of missing heritability
because of the inability to identify causal variants and genes in complex traits (Tam
et al., 2019). Also, GWAS studies have high false positives and low replication, so
this methodology has fallen short in identifying novel risk loci associated with rare
diseases such as OVCA (Auer & Lettre, 2015; Tam et al., 2019).
1.5 Identifying novel risk loci TP53I3-S252* in HBOC patients
To address the issue of missing heritability in HBOC, WES is conducted on
a cohort of 48 Caucasian women diagnosed with high-grade ovarian cancer.
These woman have a personal history of breast cancer or a family history of breast
and/or ovarian cancer (Stafford et al., 2017). During the time of sample retrieval,
the guidelines for genetic testing for HBOC was limited to assessing for pathogenic
mutations in BRCA1 and BRCA2. Thus, these women are an ideal cohort for up to
date genetic panel testing to identify clinically actionable mutations. The cohort can
also highlight the importance of identifying novel risk mutations in nonpanel/candidate genes. After WES of the germline DNA, in silico single nucleotide
(SNP) assessment is conducted to filter down to clinically actionable or candidates
variants for functional assessment. There are 5 clinically actionable mutations in
panel genes and 11 additional truncations in non-panel genes involved in DNA
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repair and cell cycle regulation (Lopes, Chaudhry, Lopes, Levin, & Tainsky, 2019;
Stafford et al., 2017).
Of particular interest is the pre-mature stop gain mutation in Tumor Protein
p53 Inducible Protein 3 (TP53I3). The nonsense mutations is found in two of the
48 patients, OCJ19 and OCG14. The TP53I3 gene is unique because it is a
quinone oxidoreductase (Porté et al., 2009), involved in the DNA damage
response (Contente, Dittmer, Koch, Roth, & Dobbelstein, 2002; B. Li et al., 2013),
and p53-mediated apoptosis (Lee et al., 2010; Polyak, Xia, Zweier, Kinzler, &
Vogelstein, 1997). Identifying the truncation in TP53I3 resulted in the expansion of
in silico SNP assessment to include genes that are part of the conserved
programmed cell death pathway way, apoptosis.
1.6 TP53I3 function in apoptosis and oxidative stress
1.6.1 Functional overview
TP53I3, formally known as PIG3, is located on chromosome region 2p23.3
(Figure 2). It was originally discovered as a downstream transcriptional target of
p53 prior to the understanding of its role in apoptosis (Polyak et al., 1997). Its
coding region consists of 5 exons and there are two full-length mRNA variants with
different 5’UTR regions. At the N-terminus, there exists a nuclear localization
sequence (Lee et al., 2010). The C-terminus is homologous with quinone
oxidoreductases (QOR) (Porté et al., 2009). Alternative pre-mRNA splicing events
can cause the skipping of exon 4 and result in the splice variant PIG3AS (Nicholls
et. al., 2004). TP53I3 is found in most vertebrates except rodents, but it is present
in rabbits (Polyak et al., 1997). The gene sequence is a homolog for the plant
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gene TED2 which is a plant NADPH oxidoreductase and involved in the formation
of plant meristems by apoptosis (Polyak et al., 1997). In mammals, the TP53I3
sequence is most similar to NADPH-quinone oxidoreductase, ζ-crystallin, a potent
generator of reactive oxygen species (ROS) (Porté et al., 2009). Therefore, TP53I3
is a QOR which is part of the medium chain reductases (MDR) superfamily. The
coding sequence contains a conserved binding motif for medium chain
dehydrogenases/reductases (MDR). There are also 13 residues in the amino acid
sequence of TP53I3 that NADP+ can bind to, 7 of which are conserved (Porté et
al., 2009). TP53I3 has also been associated with DNA damage response by
effecting phosphorylation of CHK2 and γH2AX (Lee et al., 2010).
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Figure 2: TP53I3 gene structure and domains
TP53I3 is located on chromosome 2p23.3 and is 1653 nucleotides in length. There
are two p53 binding sites at the promoter region including the polymorphic
microsatellite (TGYCC)n. The nuclear localization site is close to the N-terminus
and the homologous MDR superfamily sequence is near the C-terminus. There
are 13 NADP+ binding sites, all within the sequence that shares homology with the
medium chain reductase (MDR) family.
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1.6.2 Three-dimensional structure of TP53I3 proposed in 2009
In 2009 the crystallographic structure of TP53I3 was determined in the
presence of NADP+ to determine the protein’s enzymatic function (Porté et al.,
2009). The following will explain the protein structure and important domains. Two
constructs were crystallized and had identical subunits making the TP53I3 a stable
homodimer. The protein structure contains two important domains, a catalytic
domain (Met1 – Ala119 and Leu265 – Gln332) and a cofactor-binding domain
(Ala120 – Ser264). In-between these two domains is a deep cleft for the NADP +
molecule to bind to. There are 13 amino acid residues that can bind to NADP+, 7
of which are conserved in the TP53I3 sequence. One of the binding sites for
NADP+ resides in the conserved binding motif (A/G)XXSXXG and can be found in
many other quinone oxidoreductases (Edwards et al., 1996). A missense change
from a serine to a valine (TP53I3-S151V), results in enzymatic inactivation due to
steric hindrance and preventing NADP+ from binding. NADPH binding to TP53I3
was determined by the quenching of protein fluorescence, the 2’ phosphate group
binds to Gly173, Lys173, and Tyr192. Many NADPH dependent MDRs are
characterized by having a glycine at the C-terminal end of the nucleotide binding
domain. The corresponding residue in TP53I3 would be the conserved Gly173.
This suggests that TP53I3 is an NADPH dependent enzyme.
The active binding site is formed by amino acids Asn40, Ala42, Met45,
Tyr51, Leu51, Leu63, Glu123, Thr127, Leu63, Glu123, Thr127, Leu240, Leu255,
Phe256, and Leu265. TP53I3 NADPH-dependent reductase activity was tested
with known QOR and ζ-crystallin substrates. The protein exhibited strong
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enzymatic activity with 1,2-naphthoquinone (1,2-NQ), an ortho-quinone. Kinetic
analysis was conducted with wildtype TP53I3 or TP53I3-S151V in the presence of
the 1,2-NQ substrate (Porté et al., 2009). The Vmax determines the rate of reaction
when the substrates saturate the enzyme and is dependent on the affinity of the
substrate to bind to the enzyme. To determine if a substrate has a high binding
affinity with an enzyme, the Michaelis constant is measured (Km) (Johnson &
Goody, 2011). The Km measures the concentration of the substrate which permits
the enzyme to achieve half Vmax. The second order rate constant Kcat/Km is the
catalytic efficiency of the enzyme (Johnson & Goody, 2011). The Kcat/Km for
TP53I3-S151V in the presence of 1,2-NQ was much higher than wildtype TP53I3
indicating the mutant is enzymatically inactive (Porté et al., 2009).
The structure of 1,2-NQ substrate fits into the active binding site of TP53I3
in the appropriate orientation. The production of ROS was detected in the presence
or absence of 1,2-NQ substrate, TP53I3 enzyme and/or cofactor NADPH. There
was a significant increase in ROS production after a complete reaction consisting
of the enzyme, substrate, and cofactor, compared to when there was an absence
of one of the components. Intracellular ROS was measured with the 2’,7’dichlorodihydrofluorescein diacetate (DCFHDA) in HCT-116 with unmodified
TP53I3, overexpressed TP53I3, TP53I3-S151V or phorbol 12-myristate 13acetate (PMA; positive control).

The TP53I3-S151V mutant resulted in a

significant decrease in intercellular ROS production compared to cells with
overexpression TP53I3 or PMA positive control. So a disruption in the active site
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can affect binding affinity for ortho-quinone substrates, causing a hindrance in
ROS production.
1.6.3 Transcriptional Regulation of TP53I3
There are two p53 binding sites in the promoter region of TP53I3 (Figure
2). The first is 308 nucleotides upstream of the transcription start site and is the
classic 20 base pair p53 binding sequence. The second preferential binding site,
is the polymorphic penta-nucleotide microsatellite sequence (TGYCC)n positioned
between 412 and 517 nucleotides downstream of the transcription start site
(Contente et al., 2002). The microsatellite is considered to be the first of its kind to
functionally interact with a transcription factor (Contente et al., 2002). Variations of
these repeat sequences have been associated with many different cancers
including squamous cell carcinoma of the head and neck (Guan et al., 2013),
myeloid leukemia (Nomdedéu et al., 2004), breast carcinoma (Gorgoulis et al.,
2004), lung carcinoma (Gorgoulis et al., 2004) and invasive bladder cancer (Ito et
al., 2006). There were four different motif sizes found in a population of healthy
individuals, 10, 15, 16 or 17 with a frequency of 5.1%, 63%, 21.4%, and 11.5%
respectively. The greater the number of TGYCC repeats, the stronger the
interaction with p53 (Contente et al., 2002). Transcriptional activation of TP53I3
can also be regulated by p63 and p73 through the penta-nucleotide microsatellite
region and mutated p53 also interacts with the motif but not as strongly (Contente
et al., 2002).
TP53I3 is also transcriptionally regulated by alternative splicing, resulting in
the skipping of the fourth exon in the pre-mRNA. As a result, there is co-expression
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of the splice variant (PIG3AS) with the full-length variant (Nicholls et al., 2004).
The splice variant is made up of 248 amino acids lacking most of the 5’UTR region.
Unlike the full-length variants, the PIG3AS C-terminal domain is not homologous
with QOR (Kotsinas et al., 2012). Under normal conditions, there is a preference
for the expression of the full-length variant. However, under ultra-violet irradiation,
there is a preference for expression of PIG3AS which has a short life span and is
considered non-functional (Nicholls et al., 2004). Therefore, it is possible that
defects in the C-terminus of the full-length variant will, at the very least, affect ROS
production and cellular apoptosis.
1.6.4 Apoptosis
To fully appreciate the role of TP53I3 in apoptosis, a basic understanding
of the mechanism is necessary. Apoptosis is an essential mechanism that initiates
the programming of cell death and the maintenance of tissue homeostasis. There
are many forms of programmed cell death, and apoptosis is thought to be of
particular importance and distinction (Elmore, 2007). Apoptosis is a defense
mechanism when cells are stressed by DNA damage, external toxins, and reaction
to the immune system (Norbury & Hickson, 2001). In mouse models, it has been
demonstrated that apoptosis and necrosis can occur independently, sequentially
or simultaneously (Zeiss, 2003). To differentiate between the two processes,
morphological differences can be assessed. Necrosis is characterized by cell
swelling and dissolution of the nucleus. On the other hand during apoptosis, cells
shrink, cytosol calcium increases, and the nucleus becomes dense and compact
and eventually undergoes fragmentation (Elmore, 2007). Apoptosis is a key
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regulator of tumorigenesis and treatment response (Fulda & Debatin, 2006).
Drugs or irradiation used to target cancer cells can damage the DNA and lead to
p53-mediated apoptosis (Elmore, 2007).
1.6.5 Intrinsic apoptosis
There are two main apoptotic pathways, extrinsic/death receptor and
intrinsic/mitochondrial. Damage to the cell’s DNA elicits apoptosis primarily
through the intrinsic pathway (Figure 3). The intrinsic or mitochondrial pathway, is
of particular interest because it involves upstream transcriptional activation of p53mediated apoptosis cells. Recall, TP53I3 is transcriptionally activated by p53
binding to the polymorphic pentanucleotide repetitive motif (TGYCC) n to initiate
apoptosis. Components involved in the apoptosis process are conserved proteins
and physical association with the mitochondria. In terms of the intrinsic pathway,
when pro-apoptotic signals occur, disruption in the mitochondrial membrane
potential causes the release of cytochrome c into the cytoplasm (Elmore, 2007).
Cytochrome c pairs with apoptotic protease activating factor 1 (APAF1) and
inactive caspase-9, forming the apoptosome (Elmore, 2007). The apoptosome
hydrolyzes adenosine triphosphate (ATP) to cleave and activate. Activated
caspase-9 cleaves and activates caspases- 3, 6 and 7 followed by cell apoptosis
(Norbury & Hickson, 2001). Cleavage and activation of caspase-3 is the hallmark
of apoptosis because it promotes DNA fragmentation and cell death (Cotter, 2009).
Permeabilization of the mitochondria membrane also releases Smac into the
cytosol which promotes apoptosis by blocking inhibitors of apoptosis proteins
(IAPs) (Hongmei, 2012). The B-cell lymphoma (Bcl-2) protein family are the main
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regulators of intrinsic apoptosis. The Bcl-2 family activates pro-apoptotic or inhibits
anti-apoptotic genes. Some of the best characterized pro-apoptotic proteins are
BID, BAD, BIM, BMF, Puma and NOXA contain a Bcl-2 homology 3 domain (BH3)
(Kluck et al., 1999). Anti-apoptotic proteins BCL-2, BCL-XL, and MCL-1 have
multiple BH3 binding domains and inhibit cytochrome c release (Schuler & Green,
2001).
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Figure 3: Intrinsic apoptosis pathway
Image

source:

https://www.creative-diagnostics.com/intrinsic-apoptosis-

pathway.htm. Permission of image use granted by CD Creative Diagnostics.
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1.6.6 p53-mediated apoptosis
Tumor protein p53 regulates the expression of many genes involved in a
variety of cellular mechanisms including apoptosis, growth arrest, and
senescence. The protein consists of four conserved domains, N-terminus,
sequence-specific DNA binding, tetramization domain, and C-terminus (Pavletich,
Chambers, & Pabo, 1993). When cells are stressed, p53 is stabilized and
accumulates in the nucleus. Phosphorylation of p53 is mediated by cellular kinases
including check point kinase 1 (CHK1) and check point kinase 2 (CHK2) as well as
ataxia-telangiectasia mutated (ATM) (Kuribayashi et al., 2011; Schuler & Green,
2001). Activated p53 initiates the expression of genes leading to programmed cell
death (Shen & White, 2001). To promote apoptosis, p53 transcriptionally activates
a specific set of genes known as p53-proapoptotic genes including TP53I3 and
TP53AIP1 as well as BID, PUMA, NOXA, BAD, BAX, CASP6, and APAF1
(Kuribayashi et al., 2011). Depending on which residue is phosphorylated or
acetylated in p53, certain pro-apoptotic genes are selectively expressed.
Phosphorylation of serine 15 and 20 (Amano et al., 2009) or acetylation at 320 and
373 results in the transcriptional activation of TP53I3 (Yanagihara et al., 1991). A
subset of p53 targeted apoptosis genes also function as ROS producers, including
TP53I3. While p53 is often mutated or not functional in tumors, family members
p63 and p73 are known to compensate for its loss (Napoli & Flores, 2013).
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1.6.7 Quinone reduction reaction for ROS production and downstream
apoptosis
Low levels of ROS are important for normal cell cycle progression,
proliferation, differentiation, migration, death (Covarrubias et a., 2008), immune
response and redox reaction regulation (Schieber & Chandel, 2014). Excessive
levels of cellular ROS are detrimental to cellular integrity and can trigger oxidative
stress. Increased production of ROS has been associated with cancer, metabolic
and neurodegenerative diseases (Kehrer & Klotz, 2015). Production of ROS
involves endogenous or exogenous factors. Endogenous superoxide ROS
production occurs due to leaks in the mitochondrial electron transport chain,
specifically from complex I and II (Dickinson & Chang, 2011). Superoxides are
also produced by NADPH oxidases, xanthine oxidases, and cytochrome P450
reductases (Bae, Oh, Rhee, & Yoo, 2011). The TP53I3 protein is a quinone
oxidoreductase due to sequence with similarity with the QOR family and reactivity
with quinone substrates for ROS production (Porté et al., 2009). Under normal
conditions, TP53I3 is localized in the cytosol, a feature shared with other QOR
(Flatt et al., 2000).
Oxidative stress is an imbalance between pro-oxidative and anti-oxidative
states that leads to an increase in ROS (Schieber & Chandel, 2014). Oxidative
stress is commonly associated with causing cellular damages to age-related
processes such as cancer (Klaunig & Kamendulis, 2004). The mechanism can be
initiated through the redox reaction cycle that involves many oxidoreductases
(Oppermann, 2007). HBOC associated gene, BRCA1 and ATM are involved in the
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redox reaction by regulating ROS production (Gorrini, Harris, & Mak, 2013;
Srinivas, Tan, Vellayappan, & Jeyasekharan, 2019). During respiration, about 5%
of molecular oxygen is converted to ROS. Major ROS molecules include
superoxide (O-), H2O2, and hydroxyl radical (OH) (Pelicano, Carney, & Huang,
2004). Production of ROS changes the cellular redox state and effects the
modification of nucleic acid, proteins, and lipids which are important processes for
cancer progression. The redox cycling of quinones is initiated by oxidoreductases,
included NADPH-dependent quinone reduction and the understudied class of
QOR belonging to the MDR superfamily (Oppermann, 2007). Quinone compounds
are reduced to unstable intermediates semiquinone, by one electron, or to
hydroquinone by two electrons. Reduction to hydroquinone also requires the
presence of quinone reducing agents such as NADPH-oxidoreductase (Figure 3)
(Bolton & Dunlap, 2017; Oppermann, 2007; Porté et al., 2009). The reduction of
oxygen generates superoxide ROS which is dismutated by superoxide dismutase,
generating H2O2. The compound is then reduced to another form of ROS, hydroxyl
radicals, in the presence of a metal ion (Bolton & Dunlap, 2017). Quinones can
sustain the production of ROS leading to DNA modifications and affecting cellular
response and defense mechanisms such as apoptosis.
Potent levels of ROS increases the amount of intrinsic apoptosis (RedzaDutordoir & Averill-Bates, 2016). High amounts of ROS can activate p53 or JNK
resulting in the activation of Bcl-2 proteins. Oxidation of cardiolipin and the
depolarization of the mitochondrial membrane releases cytochrome c into the
cytosol (Figure 3) (Redza-Dutordoir & Averill-Bates, 2016). Cytochrome c forms
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the apoptosome triggering the downstream caspase cascade activation effect and
eventual apoptosis (Cotter, 2009).
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Figure 4: Quinone reduction to reactive oxygen species (ROS)
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1.6.8 How TP53I3 connects oxidative stress and DNA Damage Response
(DDR)
In order for DDR proteins such as TP53I3 to properly function, recognition
of DNA breaks by ATM is required. The protein kinase then activates the p53
antitumor cellular response causing cell cycle arrest, apoptosis or senescence.
Also activated by p53 are DNA repair mechanisms that are compromised in
malignant cells. Because TP53I3 has a role in two conserved mechanisms, it is
thought that loss of function could be toxic to both normal and cancer cells (A
Kotsinas et al., 2010).
There is a proposed model for how TP53I3 functions in normal and
malignant cells that ties together the effects of oxidative stress and DDR (A
Kotsinas et al., 2012). In normal cells under genotoxic stress, DNA damage
response (DDR) stabilizes p53 and TP53I3 expression is increased. During low
levels of genotoxic stress, DDR TP53I3 triggers DNA repair. When DNA is
exposed to genotoxic stress, p53 increases the expression of pro-oxidant TP53I3
even more. This causes lethal levels of ROS production and eventual cellular
apoptosis. When malignant cells with wildtype p53 are under continuous oxidative
or genotoxic stress, mutations accumulate. A significant amount of TP53I3 is
shuttled to the nucleus to support DDR which adds to the sub-lethal ROS
production, maintaining the oxidative stress conditions. The continuous support of
DDR by TP53I3 leads to p53 loss or mutation. However, p63 or p73 can
compensate for the loss of p53 to support the positive feedback loop of TP53I3
response to DDR and ROS production.
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1.6.9 DNA damage response
DDR involves the mechanisms that sense and signal the presence of DNA
(Harper & Elledge, 2007). DNA repair processes include proteins that are highly
conserved. Mutations in these proteins can lead to defects in DNA repair and
increase predisposition to cancer. Types of DNA damage include bases mismatch,
single strand breaks, double strand breaks (DSB), insertions, deletions, bulky DNA
lesions, oxidized/deaminated bases, methylated (O6 or N7) guanine, pyrimidine
dimers, interstrand crosslinks and intrastrand crosslinks (Blanpain, Mohrin,
Sotiropoulou, & Passegué, 2011; Pilié, Tang, Mills, & Yap, 2019). Two
mechanisms involved in DSB are non-homologous end joining (NHEJ) and
homolgous recombination repair (HRR). Many genes that drive HRR are part of
the HBOC panel, including

BRCA1, BRCA2, ATM, CHK2, PALB2, RAD50,

RAD51D, and NBN (da Cunha Colombo Bonadio, Fogace, Miranda, & Diz, 2018;
Liang, Han, Romanienko, & Jasin, 1998).
DSB are made by damaging agents like ionizing radiation, radiomimetic
drugs (Limoli, Giedzinski, Bonner, & Cleaver, 2002), replication blocking lesions
(Bosco et al., 2004); ROS production (Srinivas et al., 2019) and topoisomerase I
and II inhibitors (Degrassi, Fiore, & Palitti, 2004). The inability to repair DSBs can
increase cell death or cause chromosomal changes causing genomic instability
and the production of cancer cells (Shrivastav, De Haro, & Nickoloff, 2008). The
presence of DNA double stranded breaks (DSBs) in eukaryotic cells can be
repaired by two main mechanisms, HRR or NHEJ. Homologous recombination
repair (HRR) is considered to be a more “error-free” mechanism because there is
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less chance of spontaneous mutation formation compared to NHEJ repair (Liang
et al., 1998). The determination for which mechanism should be used depends on
how the double-stranded break (DSB) was created. For example, if replication fork
stalling is recognized by the Fanconi Anemia complex, and will eventually lead to
the signaling of BRCA1 for repair by HRR (Goldstein & Kastan, 2015). On the other
hand, DSBs formed by IR can be repaired by HRR or NHEJ either pathways. HRR
is a highly conserved mechanism due to the exchange of genetic information
between allelic sequences (Liang et al., 1998; San Filippo, Sung, & Klein, 2008;
Sung & Klein, 2006). HRR is vital for DNA repair, replication, meiotic chromosome
segregation, and telomere maintenance. The HRR mechanism involves the
broken ends of the DNA to use the homologous sequence as am repair template,
from the sister chromatid or foreign DNA at the S and G2 cell cycle phase.
When a DSB is detected, ATM phosphorylates H2AX histone family
member X (H2AX). The DNA damage checkpoint protein 1 (MDC1) binds to the
phosphorylated γH2AX and accumulates at sites of DNA damage. DSB repair
proteins MRE11, RAD50 and NBS1 form the MRN complex which localizes to the
DSB for stabilization and prevention of chromosome breaks. The 5’exonuclease
activity of C-terminal binding protein-interacting protein (CtIP) creates singlestranded overhangs and the replication protein (RPA) binds to the 3’ singlestranded overhangs (Symington, 2014). RPA is replaced by RAD51, breast cancer
1 (BRCA1) and 2 (BRCA2) proteins to create filaments on the DNA. A homologous
sequence from the sister chromatids or foreign DNA is identified by the 3’ overhang
of Rad51 (Symington, 2014; Tang et al., 2019). Proliferating cell nuclear antigen
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(PCNA) produces the deleted DNA fragment which was once broken. Lastly, a
Holliday junction is made after the formation of the new DNA fragment and the
original DNA sequence is restored (Figure 5).

29

Figure 5: Homologous Recombination Repair (HRR) mechanism
Image source: https://doi.org/10.3389/fgene.2019.00551. Permission of image use
granted by Dr. Wen-Tao Ma from the Department of Preventative Veterinary
Medicine at Northwest Agriculture and Forestry University, Yangling, China.
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Mutations in genes involved in DBS repair can be more detrimental than
exogenous factors, whether they occurred in the germline or somatically.
Approximately 40-50% of all ovarian cancers exhibit a deficiency in homologous
recombination repair mechanisms (Elvin et al., 2017). Germline mutations in
BRCA1 and BRCA2 are key in disrupting HRR (da Cunha Colombo Bonadio et al.,
2018). Breast and ovarian cancer were initially associated with HRR impairment
due to mutations in BRCA1 and BRCA2 (da Cunha Colombo Bonadio et al., 2018;
Miki et al., 1994; Wooster et al., 1995). Other HRR genes associated with cancer
risk include RAD51, CtIP, RAD51B, RECQL4, BLM, WEN and NBS1 (Helleday,
2010). The expression of RAD51 is correlated with increased responsiveness to
topoisomerase II inhibitor etoposide (Helleday, 2010). Platinum-based therapies
are another standard of care with HBOC patients because of mutations in HRR or
Fanconi Anemia genes, and are very responsive to treatment (Whitby, 2010).
Targeted therapy regimens incorporating the use of PARP inhibitors are also
beneficial for patients who carry germline mutations in either BRCA1 or BRCA2
(Coleman et al., 2015).
The role of TP53I3 in the DNA repair mechanism is not well defined.
However, our recent work determined that it is involved in HRR (Lopes et al.,
2019). The knockdown of TP53I3 in HeLa-DRGFP cells resulted in a significant
decrease in HRR induction (Lopes et al., 2019). Approximately 30% of TP53I3 is
localized in the nucleus and the other 70% in the cytosol (Lee et al., 2010).
Knockdown of TP53I3 in U2OS and HeLa cells negatively affects the intra-S phase
and G2/M DNA damage checkpoints (Athanassios Kotsinas et al., 2012; Lee et
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al., 2010). Additionally, TP53I3 depletion increased cell sensitivity to UV and
radiomimetic drugs. Under normal conditions when DDR signaling occurs TP53I3
co-localizes with p-H2AX and 53BP1. When expression of TP53I3 is lost in cells,
in the presence of genotoxic stress, there is significant reduction in CHK1, CHK2
and γH2AX (Lee et al., 2010). Breast cancer patients with high expression of
TP53I3 and BRCA1 have a significantly higher overall survival. BRCA1 is also
thought to regulate TP53I3 in a p53-dependent manner (Zhang et al., 2015). In
HCT116 cells, overexpression of BRCA1 increased expression of TP53I3 and p53.
In p53-null HCT116 cells, overexpression of BRCA1 did not induce TP53I3
expression (Zhang et al., 2015). Added to the fact that two of our HBOC patients
carry a TP53I3 germline truncation (Chaudhry et al., 2017; Lopes et al., 2019;
Stafford et al., 2017), it would be beneficial to determine the effect of that mutation
on repair of DSB with HRR for potential targeted therapy options.
1.6 Personalized therapy in clinical cancer care
There are two major issues with chemotherapy, drug resistance and relapse
of the patient after remission (Leary, Heerboth, Lapinska, & Sarkar, 2018). One
solution to mitigate both problems is personalized cancer care based on a patient’s
molecular genetic profile. Additionally, targeted therapy can result in improved
patient outcome. Cancer cells are most sensitive to drugs that do not allow for
repair of DNA breaks so that they can eventually die due to the potent amount of
damage. In many cancers, including breast and ovarian, one of the standard
therapy options is platinum-based agents (Martin, Hamilton, & Schilder, 2008;
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Pennington et al., 2014; Reed, 1998). However, platinum-based therapies can
often lead to resistance or reoccurrence (Moiseyenko et al., 2014).
Another chemotherapy drug given to HBOC patients is the topoisomerase
II inhibitor etoposide, which targets HRR-deficient cells and is involved in ROS
production. Relapsed EOC patients are often given a treatment regimen that
incorporates the usage of etoposide (Konstantinopoulos, Ceccaldi, Shapiro, &
D’Andrea, 2015). Etoposide treatment of EOC with BRCA1/2 mutations have a
higher response, longer time to resistance and better overall survival (Safra et al.,
2011). Radiomimetic drug bleomycin inhibits DNA synthesis, B-cell, T-cell and
macrophage proliferation (Muller, Yamazaki, Breter, & Zahn, 1972). Bleomycin
also reacts with oxygen to form superoxide and hydroxide ROS (Wallach-Dayan
et al., 2006). It is often used in combination with etoposide and/or cisplatin.
Mitomycin C (MMC) is a chemotherapy drug that alkylates DNA to inhibit synthesis
and forms interstrand cross-links like the platinum based drug cisplatin. It is a
treatment option for anal, bladder, breast, cervical, colorectal, head and neck and
non-small cell lung carcinomas. Ovarian cancer patients with germline BRCA1/2
mutations have had a complete response, partial response or disease stabilization
to MMC (Moiseyenko et al., 2014).
1.6.1 Cancer therapies targeting intrinsic apoptosis
Most of the cancer therapies generate pro-death signals that initiate
apoptosis of tumor cells. Apoptosis is no longer reversible once the outer
membrane of the mitochondria is permeabilized (Elmore, 2007). Defects in the
intrinsic apoptosis pathway affects tumor cells responding to chemotherapy and
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can result in resistance. Discovering new therapies that target genes involved in
intrinsic

mitochondrial

apoptosis

would

be

revolutionary

in

mitigating

chemotherapy resistance. TP53I3 is a p53 regulated pro-apoptotic gene and part
of a larger group of genes involved in regulating mitochondrial membrane potential.
Additionally, its role in reacting as an enzyme in the presence of other quinone
substrate contributes to ROS production under normal and stressed cellular
conditions (Athanassios Kotsinas et al., 2012). Thus, with what is known about
chemotherapy resistance, mutated TP53I3 could result in chemotherapy
resistance and become the bases for creating new therapies to target intrinsic
apoptosis.
1.7 Functional assessment of TP53I3-S252* to address missing heritability
The issue of missing heritability creates a knowledge gap in determining
and understanding an individual’s true genetic risk of HBOC. A streamlined method
of identifying novel risk loci is used in this study to exemplify the advantages of
using NGS data analysis and wet lab techniques in combination. I conducted in
silico assessment of 48 Caucasian non-Finnish women diagnosed with ovarian
cancer and a personal or family history of epithelial cancers. WES analysis
identified 13 truncations in apoptosis genes, including a rare pre-mature stop-gain
mutation TP53I3-S252* (Stafford et al., 2017) in two patients. The truncation in
TP53I3 will be functionally assessed in vitro to determine its impact on cancer
related pathways DNA repair and apoptosis, as well as determining sensitivity or
resistance to chemotherapy. The nonsense mutation is upstream of three residues
important in maintaining the binding affinity for QOR substrates such as NADP+.
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(Porté et al., 2009). When a QOR binds to the enzyme at the active site, ROS is
produced in order for damaged cells to undergo apoptosis. Therefore, the TP53I3S252* truncation could prevent the substrates from binding to the active site and
prevent ROS production and reduce apoptotic events.
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CHAPTER 2 – METHODS
1.1 Acquiring Samples and Determining Tumor Histology
Patient samples were acquired through the Karmanos Cancer Institute
Genetic Registry (KCIGR). An IRB was approved for bio-specimens from females
with a personal or family history of breast and/or ovarian cancer. From 1999-2013
over 800 DNA samples were collected at which time HBOC genetic screening only
involved BRCA1/2 risk assessment using BRCAPRO and Myriad II. BRCAPRO is
a Bayesian model that determines the probabilities that a patient’s BRCA1 or
BRCA2 mutation accounts for the pattern of breast and ovarian cancer in first- and
second-degree relatives (Parmigiani, Berry, & Aguilar, 1998). Myriad II identifies
putative BRCA1/2 mutation carriers based on patient ethnic ancestry (Ashkenazi
Jewish or non-Ashkenazi Jewish), breast cancer age of onset (age ≤50 years), and
the presence of ovarian cancer in the patient or first- or second-degree relatives
(Frank, 1999).
Of the 800 DNA samples, 89 were from high-risk Caucasian women with a
personal history of OVCA. Participants were BRCA1/2 mutation carriers or
BRCA1/2 wildtype after full gene sequencing, BART (BRCAnalysis rearrangement
test) or testing for the three common Ashkenazi Jewish mutations. Participants
who tested positive for pathogenic BRCA1/2 germline mutations were excluded
from our study sample, resulting in a final count of 48 Caucasian women with one
mother-daughter pairing. All subjects gave informed consent, allowing for the
collection of blood samples and access to medical records. The protocol
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(HIC#024199MP2F(5R)) was approved following a Full Board Review by the
Human Investigation Committee at Wayne State University, Detroit, Michigan.
Classification of tumor histology included 26 serous, 5 endometrioid
carcinoma, 4 adenocarcinoma, 1 mucinous, 1 clear cell and 9 undefined/unknown.
Tumor grades included 6 moderately differentiated, 24 poorly differentiated and 1
well differentiated. Primary diagnosis was determined to be ovarian cancer for 43
patients with a secondary diagnosis of breast cancer (n = 6), colon cancer (n = 2),
uterine cancer (n = 1) or melanoma (n = 1). The other 5 patients had a secondary
diagnosis of OVCA, with primary being breast cancer (n = 4) or cervical cancer (n
= 1) (Table 2).
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Histology

N

%

Serous

26

54

Endometrioid

5

10

Mixed

4

8

Adenocarcinoma, NOS

2

4

Clear Cell

1

2

Mucinous

1

2

Unknown

9

19

Stage

N

%

I

8

17

II

5

10

III

23

48

IV

3

6

Unknown

9

19

Grade

N

%

Grade 1

1

2

Grade 2

6

13

Grade 3

31

50

Unknown

17

35

Personal and Family History

N

%

Personal BC/OVCA diagnosis <50 years of age

15

31

Personal second primary cancer diagnosis

12

25

Personal/family history BC

31

65

Family history of OVCA

14

29

Family history of epithelial cancer

47

98

Table 2: Tumor Histology and prevalence of ovarian cancer (OVCA)and
breast (BC) in the patient cohort
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1.2 Whole exome sequencing and candidate gene analysis
DNA from peripheral blood samples was isolated by the Karmanos Applied
Genomics Technology Center, Detroit, MI using Qiagen QIAamp DNA mini kit and
WES was performed using Illumina Nextera Rapid Capture Kit. Samples were
processed as followed:
1. Samples were demultiplexed with Illumina CASAVE 1.8.2.
2. Read quality assessment was conducted with with FastQC (Andrews,
2010).
3. Alignment to the human reference genome (hg19) (Lander et al., 2001)
using Burrows Wheeler Aligner (BWA) (H. Li & Durbin, 2009).
4. For the removal of PCR duplicates, samtools was utilized (H. Li et al., 2009).
5. Local realignment, Qscore recalibration, variant calling, and filtering was
performed using the GATK Unified Genotyper (DePristo et al., 2011).
6. Subsequent filters were implemented to remove SNPs of low quality, read
count or confidence:
a. SNP mapping quality = 0 for four or more alignments and the
number of alignments that mapped ambiguously were in more than
1/10 of all alignments.
b. SNP reads less than 5 reads.
c. SNP quality is less than 50
d. QD score (variant confidence) is less than 1.5
7. Variant Call Format (VCF version 4.1) files were created with Genome Trax
BIOBASE biological databases analysis software.
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8. Illumina BaseSpace VariantStudio application v2.2.4 and iVariantGuide
were used for variant annotated and predicted variant effects was
determined with snpEff (Cingolani et al., 2012).
Our focus was to identify clinically actionable and novel loci in the 25 genes
currently on the HBOC genetic testing panels by Ambry OvaNext and Myriad
MyRisk. Also included were non-panel genes important to DNA damage response,
cell cycle regulation or apoptosis and genes disease causing mutations associated
with OVCA designated by HGMD (Table 3). To determine the impact of a variant
on cancer risk, various clinically curated databases and bioinformatics tools were
used including ClinVar (Landrum et al., 2018), HGMD (Stenson et al., 2017),
COSMIC (Forbes et al., 2008), dbSNP (Sherry et al., 2001), gnomAD (Karczewski
et al., 2019), SIFT (Ng & Henikoff, 2003), and PolyPhen (Adzhubei, Jordan, &
Sunyaev, 2013). To focus on the most interesting variants very conservative filters
were applied:
1. Only exonic SNPs
2. Moderate to high impact on protein function (frameshift, nonsense, and
missense)
3. A minor allele frequency of the mutations is less than 0.02 rare in the
European, non-Finnish population
4. Predicted to be damaging by predictive algorithms SIFT and/or PolyPhen,
Variants that fit these criteria were confirmed by forward and reverse strand
Sanger sequence (Table 3).
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Table 3: List of DNA repair, cell cycle regulation and apoptosis genes
investigated for the variant assessment of HBOC patients (Stafford et al., 2017).
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1.3 Confirming variants of interest
Validation of SNPs involves PCR amplification and Sanger sequencing.
Primers targeted the genomic DNA in the patient carrying the SNP were created
using Primer3Plus and Thermo Fisher Primer Designer Tool application. Primer
constructs were obtained from Sigma-Aldrich. Forward and reverse primers were
between 200 – 100 base pairs away from the SNP, had a GC content of
approximately 50% and annealing temperature between 50ºC and 52 ºC (Table
4).
1.3.1 PCR amplification
Primers were re-suspended in sterile water for a stock concentration of 100
µM and a working stock is diluted to 10 µM. PCR amplification was conducted
using the QIAGEN Fast Cycling PCR Kit (203743).
One reaction 20 µL consists of:
1. 10 µL Qiagen Fast Cycling PCR Master Mix
2. 2 µL CoralLoad Dye
3. 2 µL forward primer (10 µM)
4. 2 µL reverse primer (10 µM)
5. 2 µL sterile H2O
6. 2 µL of 25 ng/uL patient DNA/positive control/ negative control. The
Positive control consists of normal fibroblast genomic DNA and the negative
control was water.
PCR amplification protocol requires denaturing, annealing and elongation,
1. DNA heated at 95°C for 5 minutes for original denaturing.
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2. PCR Cycle begins with denaturing for 5 seconds at 96°C.
3. Annealing between 50 °C and 62 °C depending on primer specification.
4. Elongation for 15 seconds at 68°C for 15 seconds PCR Cycle ends.
5. Repeat steps 2 to 4 for 36 cycles.
6. Final elongation at 72 °C for 2 minutes.
1.3.2 Agarose gel electrophoresis
DNA amplification occurred was confirmed using gel electrophoresis. DNA
bands are separated by size, the smaller the fragment size the lower it migrates
down the agarose gel. Since DNA is negatively charged, when applying electric
current the fragments will move toward the positive electrode. The CoralLoad binds
to the DNA and emits red fluorescence. A 1% agarose gel made with 1X TAE
buffer was used (Thermo Fisher 16500100). Prior to casting the gel, propidium
iodide was added to allow for the visualization of the product. The gels are
submerged in 1 x TAE buffer (40 mM Tris base, 2 mM EDTA, 20 mM Acetic Acid,
pH 8.5). Approximately, 2 – 5 µL of the PCR product was loaded along with 2 µL
of a 100 base pair DNA ladder (Invitrogen™ 100 bp DNA ladder, 15628019). The
gel was run at 100 volts for 60 minutes and visualized under the Odyssey LI-COR
scanner.
1.3.3 Sanger sequence confirmation
After confirming that the target region had been properly amplified with gel
electrophoresis, the amplified genomic DNA from the PCR products were purified
using the QIAGEN QIAquick PCR Purification Kit (28106).The concentration of the
purified genomic DNA was quantified using the Nanodrop 2000. The sequencing
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reactions were assembled and sent to Genewiz. One reaction consists of 5 µL of
forward or reverse primer, 2 µL of 25 ng/ µL amplified genomic DNA and 8 of µL
sterile water.
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Gene

SNP

AA Change

Forward

Reverse

PIK3C2G

rs61757718

*1446S

CAGAGCTCCAAGGACATGTC

CTGCTTTTAACTGTAGGCACAC

TP53I3

rs145078765

S252*

TCTGAAATCGGGTTCCCTCT

AGGCCTCATAAATGGTGAACTT

TP53AIP1

rs141395772

Q22fs

GCAAAAGACCGTCTCGGTTTTC

CCTAACAACAAATGAGGAGAAGCCA

TP53AIP1

rs140191758

S32*

GCAAAAGACCGTCTCGGTTTTC

CCTAACAACAAATGAGGAGAAGCCA

BCLAF1

rs61731960

E403*

GTTTGACTTCAGGACGGTGA

AGGATCAGAGAAAGGGAGGG

BCLAF1

rs140096922

H847fs

TGTAAAACGACGGCCAGT

CAGGAAACAGCTATGACC

PPP1R15A

rs139708522

E160*

GAGAAACACTGGGGCTGAAA

TGTGTGCCTTTTCCTCCTTC

DOCK1

rs768625958

D248fs

AACAGACAAGCCAAGTTTGC

GGCAGGCACCATTCTAAATG

NLRP1

rs771551366

R138fs

CCCTATCCTTCCTCTGCTGT

GTTGGCCCAATAAAGCACAG

PTH

N/A

K85fs

TGTATTGTTGCCCTACACTGT

TACCTGCAAAAGACATGGCT

ANGPTL4

rs747940485

G275fs

ATGGCTCAGTGGACTTCAAC

GCATGTAAGGAAGAGGTGGG

NOD2

N/A

W289*

TCAGTCTCGCTTCCTCAGTA

TGCAGAAGGTTGAAGAGCAG

GZMM

rs200398398

Q161*

TAGCTGGACGGGAAAGTGAA

GCTAAACCTGTCTGAGCCTC

Table 4: PCR primer sequences for SNP confirmation found apoptosis
genes.
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1.4 Cell lines and Cell culture
A variety of different cell lines were used to find the best in vitro model for
DNA damage and cell death pathways. Epithelial ovarian cancer cells SKOV-3 are
derived

from

a

64-year-old

Caucasian

female

with

ovarian

serous

cystadenocarcinoma (Fogh, Fogh, & Orfeo, 1977). SKOV-3-DRGFP cells were
gifted by Dr. Z Ping Lin from Yale University School of Medicine (Lin, Ratner,
Whicker, Lee, & Sartorelli, 2014). However, SKOV-3 cells are p53 null and the
population only exhibited a 2% induction of the DNA repair mechanism. Subcloning was attempted on the SKOV-3-DRGFP cells, but the HRR induction rate
did not improve significantly. High grade ovarian serous adenocarcinoma
OVCAR8 cells were also evaluated for functional assessment of DNA repair and
cell death. OVCAR-8-DRGFP was provided by Dr. Larry Karnitz from the Mayo
Clinic. However, OVCAR8 is also p53 null and induction of HRR was not
successful. Therefore, the SKOV4-DRGFP and OVCAR8-DRGFP cells were not
used for in vitro assessment of DNA repair and cell death.
HeLa cells are immortalized and derived from cervical cancer cells from a
31-year-old African American woman. HeLa cells are well characterized and have
been used across a variety of research topics in the medical fields. HeLa-DR-GFP
cells were provided by Dr. Jeffery Parvin from Ohio State University. The induction
of HRR after DNA DSB in HeLa-DRGFP ranged from 10% – 20% of the cells within
the population.
All cells types were maintained in Dulbecco’s Modified Eagle Medium
(DMEM; 31600-034), low glucose, pyruvate with 10% fetal bovine serum (Hyclone,
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SH30071.03IR), 1% penicillin-streptomycin (Gibco™, 15070063), and 0.5 - 1.5
µg/mL puromycin for selection of pDR-GFP (InvivoGen, ant-pr-1).
1.5 Transfection reagent, siRNA and antibodies
The focus of this work was to determine the effect of candidate apoptosis
genes, TP53I3, and the associated nonsense mutation that two of the HBOC
patients carried on cellular function using transient transfection. Transient
transfection employs exogenous nucleic acid for a limited period of time followed
by functional assays. For protein knockdown, high quality and pure siRNAs were
used targeting the 3’UTR not contained in the plasmid expression vectors.
Exogenous TP53I3 wildtype, TP53I3-S252* mutant and empty vector DNA
plasmids were delivered to the cells by transient transfection. All transfections are
conducted using jetPRIME Transfection Reagent (Polyplus, 114-15). Information
about plasmid DNA, siRNA protein knockdown, and primary and secondary
antibodies for protein quantification can be found in Table 5. Based on knockdown
efficiency, the concentration of siRNA used for all proteins was 110 picomole/well
in a 24 well plate and scaled up to the appropriate cell culture plate when needed.
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Product

Manufacturer Catalog No.

Concentration/Dilution

Hs_ TP53I3_2 FlexiTube siRNA
20 nmol

Qiagen

SI00069636

110 pmol in a 24 well plate

Hs_BRCA1_13
siRNA 20 nmol

Qiagen

SI02654575

110 pmol in 24 well plate

P53AIP1 siRNA (h) 10µM

Santa Cruz

SC-37459

110 pmol in 24 well plate

Negative Control siRNA 20 nmol

Qiagen

1027310

110 pmol in 24 well plate

PIG3 Antibody- mouse (A-5)

Santa Cruz

SC-166664

1:1000 overnight incubation

BRCA1 Antibody- mouse (D-9)

Santa Cruz

SC-6954

1:200 overnight incubation

P53AIP1- rabbit Antibody

Invitrogen

PA5-20355

1:200 overnight incubation

AC-74

Sigma-Aldrich

A53160-100UL

1:10,000 overnight incubation

Donkey anti-Rabbit IgG (H+L)
Alexa Fluor® 790

Thermo Fisher

A11374

1:10,000; 1 hour incubation

Donkey anti- Rabbit IgG (H+L)
Alexa Fluor® 680

Thermo Fisher

A10043

1:10,000; 1 hour incubation

Donkey anti-Mouse IgG (H+L)
Alexa Fluor® 790

Thermo Fisher

A11371

1:10,000; 1 hour incubation

Donkey anti-Mouse IgG (H+L)
Alexa Fluor® 680

abcam

ab175774

1:10,000; 1 hour incubation

PIG3 cDNA Clone, Human, COFPSpark® tag

Sino Biological

HG15531-ACR

N/A

Beta-actinAntibody

FlexiTube

rabbit

Table 5: Materials for knockdown, westerns, and plasmid constructs.
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1.6 Cell Lysate Preparation and Western blots
Identification of specific protein expression from a mixture of proteins can
be done using the western blotting technique (Mahmood & Yang, 2012). For the
preparation of protein mixtures, lysed cells and proteins are solubilized using icecold RIPA (Radio Immunoprecipitation Assay Buffer) with Halt™ protease (Thermo
Fisher, 87786) and phosphatase inhibitor cocktails (Thermo Fisher, 78420). Cells
are scraped and shaken for 15 minutes at 4ºC. To ensure that the DNA was
sheared, lysates are passed through a 21-gauge and incubated on ice for 30
minutes. Cell lysate are centrifuged for 10,000xg for 10 minutes at 4ºC. The total
cell lysate supernatant was transferred to a new 0.6 mL centrifuge tube. For protein
concentration, the DC™ Protein Assay was used and consisted of protein assay
reagent A (Biorad, 5000113), protein assay reagent B (5000114) and protein assay
reagent S (Biorad, 5000115). Protein concentration was quantified using the
BioTek Synergy H1 Hybrid Multi-Mode Reader. Prior to loading the gel the protein
mixture was reduced and denatured using the LI-COR loading buffer and 2mercaptoethanol (BME).
The three main parts of western blot methodology involves separating
proteins by size, transferring proteins to a membrane and targeting protein for
visualization with primary and secondary antibodies (Mahmood & Yang, 2012). For
separation of proteins, a polyacrylamide sodium dodecyl sulfate (SDS) gel was
used, the size of the protein determines the thickness of the gel. For TP53I3,
TP53AIP1 and β-actin 12% separating gel was optimal and 6% - 7.5% for BRCA1
visualization. Cell lysates (50 – 150 µg) are prepared with a 4x Li-CORE protein
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sample buffer (928-40004) and BME before running each gel. The samples and
5 µL of the protein standard marker (Biorad, 1610374) were loaded. The gel was
run at 150 – 180 volts until the dye ran off the gel. The proteins are then transferred
to a 0.45 µM or 0.22 µM nitrocellulose membrane (VWR) at 250 mA for one hour
on ice (TP53I3, TP53AIP1, and β-actin) or 30 V for 18 hours at 4ºC (BRCA1).
Membranes were removed from the transfer apparatus and set to dry for 30
minutes. Next, the blot was blocked with 5% bovine serum albumin (BSA) in 1x
Tris Buffered Saline with 0.1% Tween 20 (TBST) for 60 minutes at room
temperature. The membranes were incubated overnight with the appropriate
primary antibody diluted in 5% BSA in 1x TBST. The membrane was washed with
1x TBST for 10 minutes three times. After one hour incubation with the secondary
in the dark at room temperature, membranes were washed with 1 x TBST for 3
minutes three times (Table 5). Visualization and quantification of protein are
determined by the LI-COR Odyssey® CLx Imaging System.
1.7 TP53I3 gene editing and transfection
TP53I3 expression vector, pCMV3-C-OFPSpark-TP53I3, was acquired
from Sino Biological (HG15531-ACR). The plasmid contains an open reading
frame for the full coding sequence of TP53I3 followed by an orange fluorescent
protein (OFP) marker at the C-terminus. Using the wildtype plasmid, site-directed
mutagenesis was conducted using the Q5-Site-Directed Mutagenesis Kit from
New England BioLabs Inc. (E0554S). To emulate the mutation change in two of
our 48 ovarian cancer patients the kit was used to create the rs145078765 (c.
755C>G, S252*) truncation. The primers for the TP53I3-S252* mutant were
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forward

5ꞌ-CCCCTGTTTTAAAAAGCTACTTTTTAAG-3ꞌ

and

reverse

5ꞌ-

CCCATTGATGTCACCTCC-3ꞌ. Purified DNA of the selected mutant and wildtype
clones was conducted using the Qiagen QIAamp DNA mini kit. PCR primers were
created to sequence the open reading frame of the plasmid in order to capture the
entire coding region of TP53I3 in both the wildtype mutant plasmid (Figure 6). In a
60 mm culture plate, a 3 ng/µL concentration of unmodified transfection was
sufficiently expressed pCMV3-C-OFPSpark-TP53I3 and similar to endogenous to
TP53I3. The pCMV3-C-OFPSpark-TP53I3 will be addressed as TP53I3-WT and
the mutant plasmid will be TP53I3-S252*. Due to the orange fluorescent protein
tag on the C-terminus of the wildtype construct, the size of the exogenous TP53I3WT is 64 kDa. Mutated TP53I3-S252* mutation is 28 kDa and endogenous TP53I3
is 36 kDa. Assessment of the mutant was conducted using a transient transfection
methodology, where endogenous TP53I3 was depleted with siRNA and the
TP53I3-S252* plasmid or the TP53I3-WT plasmid or pCMV3 empty vector was
incorporated into the HeLa-DR-GFP cells. The TP53I3 siRNA targeted a region at
the C-terminus, downstream of the truncation (Figure 7).
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A

B

C

D

Figure 6: TP53I3 site-directed mutagenesis for S252* mutant.
The pCMV3-C-OFPSpark plasmid (A) carries the full coding sequence of TP53I3
and confirmed with PCR, gel electrophoresis and Sanger sequencing (C). Using
the NEB Q5® Site-Directed Mutagenesis kit, the cytosine at position 755 of the
DNA sequence was modified to guanine resulting in a pre-mature stop codon
exhibited in the OVCA cohort (B). The mutant plasmid DNA was compared to
unmodified wildtype to insure that no off-target effects occurred (D).
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>NM_147184.3 Homo sapiens tumor protein p53 inducible protein
3 (TP53I3), transcript variant 2, mRNA
AACGGCTCCTTTCTCTTCTCTTAGCAGCACCCAGCTTGCCCACCCATGCTCAAGATGGG
CGGGATGCCAGCCTGTTACATAAATGTGCCAAAAGCCTGGCCATGCCTGGAAAATGGAC
CAATCCGCCCGCCAAGAGGTTGGGTCTCGTTCCCTAGAGAGAAGGAAGTTTCCTCTCCT
TGAAGTGAGAGCTAGAATCGCACTTTCTGTCAAGCTGAGAGAAAGACTCTTTTCCAGAG
GCTAAAAGGACAAGAAAATCTGATTTGCTTGCTTCTAACTTTGCGTTTTAAAGGGGGAA
GGAGGAAAGGAAAGAGGGGGAGGGTGGTTCTGCTTAGCCCCACCCCTCCGGCTACCCCA
GGTCCAGCCGTCCATTCCGGTGGAGGCAGAGGCAGTCCTGGGGCTCTGGGGCTCGGGCT
TTGTCACCGGGACCCGCAGGAGCCAGAACCACTCGGCGCCGCCTGGTGCATGGGAGGGG
AGCCGGGCCAGGAACAATATGTTAGCCGTGCACTTTGACAAGCCGGGAGGACCGGAAAA
CCTCTACGTGAAGGAGGTGGCCAAGCCGAGCCCGGGGGAGGGTGAAGTCCTCCTGAAGG
TGGCGGCCAGCGCCCTGAACCGGGCGGACTTAATGCAGAGACAAGGCCAGTATGACCCA
CCTCCAGGAGCCAGCAACATTTTGGGACTTGAGGCATCTGGACATGTGGCAGAGCTGGG
GCCTGGCTGCCAGGGACACTGGAAGATCGGGGACACAGCCATGGCTCTGCTCCCCGGTG
GGGGCCAGGCTCAGTACGTCACTGTCCCCGAAGGGCTCCTCATGCCTATCCCAGAGGGA
TTGACCCTGACCCAGGCTGCAGCCATCCCAGAGGCCTGGCTCACCGCCTTCCAGCTGTT
ACATCTTGTGGGAAATGTTCAGGCTGGAGACTATGTGCTAATCCATGCAGGACTGAGTG
GTGTGGGCACAGCTGCTATCCAACTCACCCGGATGGCTGGAGCTATTCCTCTGGTCACA
GCTGGCTCCCAGAAGAAGCTTCAAATGGCAGAAAAGCTTGGAGCAGCTGCTGGATTCAA
TTACAAAAAAGAGGATTTCTCTGAAGCAACGCTGAAATTCACCAAAGGTGCTGGAGTTA
ATCTTATTCTAGACTGCATAGGCGGATCCTACTGGGAGAAGAACGTCAACTGCCTGGCT
CTTGATGGTCGATGGGTTCTCTATGGTCTGATGGGAGGAGGTGACATCAATGGGCCCCT

CG

GTTTT
AAAGCTACTTTTTAAGCGAGGAAGTCTGATCACCAGTTTGCTGAGGTCTAG
GGACAATAAGTACAAGCAAATGCTGGTGAATGCTTTCACGGAGCAAATTCTGCCTCACT
TCTCCACGGAGGGCCCCCAACGTCTGCTGCCGGTTCTGGACAGAATCTACCCAGTGACC
GAAATCCAGGAGGCCCATAAGTACATGGAGGCCAACAAGAACATAGGCAAGATCGTCCT
GGAACTGCCCCAGTGAAGGAGGATGGGGCAGGACAGGACGCGGCCACCCCAGGCCTTTC
CAGAGCAAACCTGGAGAAGATTCACAATAGACAGGCCAAGAAACCCGGTGCTTCCTCCA
GAGCCGTTTAAAGCTGATATGAGGAAATAAAGAGTGAACTGGAAAAAAAAAA
siRNA target sequence

Mutation

Coding region

Figure 7: TP53I3 transcript sequence and targeted regions
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1.8 Homologous Recombination Repair (HRR) Assay
Hela-DR-GFP cells provided by Dr. Jeffery Parvin from Ohio State
University School of Medicine are used for in vitro assessment of HRR. Within the
genome, the cells contain the DR-GFP plasmid which consists of two copies of
green fluorescent protein (GFP) and transfection of I-Sce1 endonuclease causes
a DSB in the GFP allele 1 containing the I-Sce1 recognition site. The truncated
GFP allele 2 serves as a donor of DNA repair, resulting in the activation of the
repaired GFP allele 1. Therefore, GFP expression is a proxy for HRR occurring in
the cells (Pierce, Johnson, Thompson, & Jasin, 1999a). To maintain the HeLa-DRGFP selection, cells were cultured with 1.5 µg/mL Puromycin (Figure 8).
Quantification of GFP expression after transfection was determined using the BD
FACSCanto II at the Wayne State University Microscopy, Imaging & Cytometry
Resources (MICR) core. To establish how proteins of interest affect the induction
of HRR, siRNAs are used (Figure 8). As a negative control, empty vector pCMV3
was used. HeLa-DR-GFP cells were seeded 24 hours prior to transfection. The
transfection complex consists of pCMV3 empty vector or TP53I3-S252* or wildtype
TP53I3 with pCBASceI, siRNA and jetprime®PRIME reagent diluted into
jetPRIME® Buffer. All conditions were conducted in triplicate for each experiment
and raw values were normalized to the positive control.
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Figure 8: Detailed protocol for HRR assay.
The HRR assay was conducted in HeLa-DRGFP cells. Knockdown and rescue
conditioned cells for protein quantification are conducted in parallel.
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1.9 Colony Survival Assay
The clonogenic assay can be used to determine a single cell’s ability to
survive and grow into a colony (Franken, Rodermond, Stap, Haveman, & van Bree,
2006). The in vitro cell assay can be used to ascertain the cell’s reproductive death
after being conditioned with various cytotoxic agents (Franken et al., 2006). To
determine how TP53I3 knockdown, TP53I3-S252* and TP53AIP1 knockdown cells
respond to chemotherapy agents the colony survival assay was utilized (Figure 9).
For each condition, 300 cells are seeded in triplicate. Conditioned cells were
treated with the IC50 of bleomycin (1.5 µM), mitomycin C (100 nM), etoposide (4
µM) or hydrogen peroxide (H2O2, 125 µM). To prevent the rapid degradation of
H2O2, it was diluted in phenol red-free and sodium bicarbonate free DMEM. Clones
were grown for seven days post-treatment then fixed and stained with 0.5% crystal
violet (Sigma-Aldrich, C0775). Surviving colonies consisting of 50 or more cells
were counted using a light microscope to determine plating efficiency and surviving
fraction.

56

Figure 9: Detailed protocol for clonogenic assay
The clonogenic assay was conducted using HeLa-DRGFP cells. Knockdown and
rescue conditioned cells for protein quantification were conducted in parallel.
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2.1 Mitosox assay for mitochondrial reactive oxygen species (ROS)
production
To detect for production of ROS in the presence of H2O2 or etoposide, the
Mitosox probe for intra-mitochondrial superoxide ROS was used (Kauffman et al.,
2016). Mitosox is a positively charged probe that accumulates and emits red
fluorescence (excitation: 510 nm, emission: 580 nm) in the mitochondria to detect
for superoxide ROS (Kauffman et al., 2016). For each treatment (H2O2 or
etoposide), cells were seeded 24 hours prior to transfection with each knockdown
condition was conducted in triplicate (Figure 10). An additional plate was used to
serve as an untreated control for knockdown conditions in triplicate. In parallel
cells were also seeded in 6 well plates for cell lysate and protein quantification.
The transfection complex includes TP53I3-252* or TP53I3 wildtype or pCMV3
DNA with siRNA and jetPRIME® reagent. Cells were then treated with etoposide
60 µM or 125 µM of H2O2 for four hours. Next, treatment was removed and cells
were washed three times with warm PBS (37ºC) and then stained with 5 µM
Mitosox for 30 minutes at 37ºC at 5% CO2 in the dark. Fluorescence intensity was
quantified using the BioTek Synergy H1 Hybrid Multi-Mode Reader.
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Figure 10: Detailed protocol for Mitosox staining
The mitosox assay was conducted in HeLa cells. Knockdown and rescue
conditioned cells for protein quantification are conducted in parallel. Untreated and
treated conditions include, Scramble siRNA + pCMV3 treated, siBRCA1 + pCMV3,
siTP53AIP1 + pCMV3, siTP53I3 + pCMV3, siTP53I3 + TP53I3-WT plasmid,
siTP53I3 + TP53I3-S252* plasmid.
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3.1 Statistical Analysis
The values reported in graphs are the mean±standard error (S.E.) from
experiments conducted in triplicate. A standard two-way student t-test was
conducted to compare all conditions to the positive control. A value of p<0.05 was
considered statistically significant.
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CHAPTER 3 – RESULTS
1.1 Identifying clinically actionable germline mutations in HBOC patients
From 1999 – 2015, 800 DNA samples of breast and/or ovarian cancer
patients were collected. I assessed the WES data of the germline DNA of 48
Caucasian patients suspected to have HBOC but negative for pathogenic
mutations in BRCA1 and BRCA2. During the period of time in which the samples
were collected, genetic panel testing had not yet been established as a standard
of care, as usually only BRCA1 and BRCA2 were analyzed. Therefore, this sample
subset was an excellent cohort to explore genetic variation associated with OVCA
because they have not undergone up-to-date genetic panel testing. The WES data
from these patients can also help identify additional mutations in non-panel genes.
Variant caller files (VCF) were created for each patient and further annotated using
the Illumina Variant Studio 3.0 application. All mutations are annotated based on
ACMG and NCCN guidelines. Variants were filtered to only include those in the
coding region, with a minor allele frequency of at most 2%. I focused on truncation
or missense annotations as well as pathogenic or likely pathogenic in ClinVar,
damaging or deleterious in Polyphen or SIFT, high or moderate in SnpEff, type
and definition in COSMIC, germline in TCGA or damaging in HGMD. Five
unrelated patients carry a clinically actionable mutation (Table 6), including a
premature stop-gain or frameshift in FANCM, RAD51D or ATM (Stafford et al.,
2017). All five truncations were cross-referenced with the HGMD database and the
FANCM R1931* (rs144567652, MAF = 0.000946) and RAD51D R206*
(rs38790683, MAF = 0.0001) nonsense mutations are reported as damaging
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mutations (DM). Patient OCJ19 carries the FANCM rs144567652 nonsense
mutation, and consistent with our study it was associated with an increased the
risk of triple-negative breast cancer (Figlioli et al., 2019; Peterlongo et al., 2015)
and hereditary ovarian cancer (Dicks et al., 2017). Additionally, patient OCJ19
carries a truncating mutation in TP53I3-S252*, an oxidoreductase involved in the
process of apoptosis.
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Table 6: Clinically actionable and novel risk loci in DNA repair genes (Lopes
et al., 2019; Stafford et al., 2017)
From left to right is gene name, SNP ID from dbSNP, the mutation was either
nonsense (*) or frameshift, gnomAD non-Finnish population minor allele frequency
(MAF), and the number of individuals in the HBOC cohort carrying the mutation.
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1.1.1

Novel risk loci in DNA repair, cell cycle regulating and apoptosis
candidate genes
To address the issue of missing heritability in HBOC, we conducted targeted

screening to identify high impact variants in genes not currently on the genetic
panels. Genetic aberrations disrupting DNA repair, cell cycle regulating and
apoptosis can result in tumorigenesis. Therefore, variants of interest were
narrowed down to those found in KEGG annotated as DNA repair, cell cycle
regulating and/or apoptosis genes (Table 5). There are eleven high impact
truncations in DNA repair and cell cycle regulating non-panel or “candidate” genes
(Stafford et al., 2017). Of particular interest was the TP53I3 S252* rs145078765
stop-gain mutation caused by the point mutation of a cytosine at position 755 to
guanine in the gene’s coding sequence (Figure 6). This nonsense mutation was
present in two unrelated patients, OCG14 and OCJ19. There are multiple
incidences of epithelial cancers in the family history for both patients including
ovarian, breast, prostate, pancreatic, stomach and melanoma (Figure 11A and B).
Patient OCJ19 also carries the FANCM R1931* (rs144567652) truncation (Stafford
et al., 2017). Her family history includes two members previously diagnosed with
pancreatic cancer or multiple myeloma (Figure 11A). HBOC syndrome is known to
increase the risk of prostate, pancreatic, male breast and melanoma in gene
variant carriers (Solomon, Das, Brand, & Whitcomb, 2012). Patient OCG14 has
siblings diagnosed with ovarian, breast, stomach, and eye cancer (Figure 11B).
Approximately 1-3% of stomach cancer patients have an inherited cancer
predisposition syndrome, including HBOC (Petrovchich & Ford, 2016). There are
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also some family members with unknown cancer diagnoses, an issue that is often
found in self-reported pedigrees.
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Gene

Consequence

Amino Acid

Exon

SNP ID

MAF

OBS

PIK3C2G

STOP LOST

*1446S

32/32

rs61757718

0.017

2

TP53I3

STOP GAIN

S252*

4/5

rs145078765

0.0016

2

TP53AIP1

FRAMESHIFT

Q22fs

3/4

rs141395772

0.007

1

TP53AIP1

STOP GAIN

S32*

3/4

rs140191758

0.0009

1

BCLAF1

STOP GAIN

E403*

5/13

rs61731960

0.007

1

BCLAF1

FRAMESHIFT

H847fs

2/13

rs140096922

0.0003

3

PPP1R15A

STOP GAIN

E160*

2/3

rs139708522

0.006

1

DOCK1

FRAMESHIFT

D248fs

8/52

rs768625958

N/A

1

NLRP1

FRAMESHIFT

R138fs

2/17

rs771551366

0.00007

1

PTH

STOP GAIN

K85fs

1/3

N/A

N/A

1

ANGPTL4

FRAMESHIFT

G275fs

6/7

rs747940485

0.0002

1

NOD2

STOP GAIN

W289*

4/12

N/A

N/A

1

GZMM

STOP GAIN

Q161*

4/5

rs200398398

0.014

1

Table 7: Candidate risk mutations in apoptosis genes
From left to right; Gene name, Consequence = modification due to the mutation,
Amino acid = translated amino acid change due to nonsense (*) or frameshift (fs)
mutation, Exon = location of truncation, SNP ID = dbSNP ID, MAF = gnomAD
non-Finnish population minor allele frequency and OBS = number of patients in
the HBOC cohort carrying the truncation.
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A

OCJ19

B

OCG14

Figure 11: Patient pedigree for carriers of TP53I3-S252*
Patient OCJ19 (A) pro-band (arrow) carries TP53I3-S252* and pathogenic variant
FANCM-R1931* and has a family history of BC and OVCA. (B) Patient OCG14
has a family history of BC and OVCA, no RRO = no intervention, A&W = alive and
well.
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As stated previously, the individuals in the HBOC cohort also carry several
truncations in apoptosis genes. Several of the truncations in apoptosis genes were
present in more than one of the 48 HBOC patients (Table 7). Of particular interest
are 12 truncating mutations in 10 genes, including TP53I3, a TP53-regulated gene.
TP53I3 is involved in both DNA damage response and p53-mediate apoptosis. To
date, there has been no germline variant in TP53I3 associated with cancer.
However, there have been several studies indicating that the gene affects the
progression of a variety of cancers including outcome of breast (Zhang et al.,
2015), NSCLC (M. Li et al., n.d.), colon (Park et al., 2017) and papillary thyroid (XU
et al., 2015). TP53I3 overexpression significantly results in an increase in breast
cancer survival (Zhang et al., 2015). Loss of TP53I3 expression promotes NSCLC,
colon and papillary thyroid cancer (M. Li et al., n.d.; Park et al., 2017; XU et al.,
2015).
Tumor Protein P53 Regulated Apoptosis Inducing Protein 1 (TP53AIP1) is
a mitochondrial protein involved in p53-mediated apoptosis. TP53AIP1 induces the
release of cytochrome c from the mitochondria and interacts with BCL-2, affecting
TP53AIP1-mediated apoptosis through regulation of the mitochondrial membrane
potential (Matsuda et al., 2002; Oda et al., 2000). Reduced expression of
TP53AIP1 has been associated with increased progression of non-small cell lung
cancer (Fang et al., 2019). Two unrelated patients carry either the Q22fs
(rs141395772, MAF=0.007) truncation or the TP53AIP1 S32* (rs140191758,
MAF=0.0009) variants in TP53AIP1. These two high impact mutations have been
identified in cutaneous melanoma (Benfodda et al., 2018). There is conflicting data
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as to whether the two truncations are associated with prostate cancer risk
(Luedeke et al., 2012a; Wang et al., 2006).
Three unrelated patients carry the same nonsense mutation in BCL2
associated transcription factor 1 (BCLAF1) (rs61731960, E403* MAF=0.007) and
another patient has a frameshift mutation (rs140096922, H847fs MAF=0.0003) in
this gene. BCLAF1 is a tumor suppressor that interacts with anti-apoptotic
members of the BCL-2 family (Cuconati & White, 2002). The BCLAF1- E403*
nonsense mutation found in our study was previously identified in four unrelated
individuals of a larger population study of germline and somatic variants in ovarian
cancer patients (Kanchi et al., 2014). An in vitro study found that colon cancer cells
deficient in BCLAF1 have decreased cell growth and colony formation. Colon
cancer cells expressing BCLAF1 were injected into nude mice. Knockdown of
BCLAF1 resulted in a decrease in tumor incidences and tumor formation (Zhou et
al., 2014).
Another mutation over-represented in the cohort was the stop lost in
Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Gamma
(PIK3C2G), which belongs to the phosphoinositide 3-kinase (PI3K) family. The
gene has a been associated with poor colorectal cancer patient outcome (A. Li et
al., 2015) and promotion of type 2 diabetes mellitus (Daimon et al., 2008). In the
case of colorectal cancer, low copy number variants in PIK3C2G resulted in an
increased risk of reoccurrence and poor survival (A. Li et al., 2015). There are five
SNPs in PIK3C2G significantly associated with HbA1c and/or insulin levels
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(Daimon et al., 2008). Diabetes negatively affects the overall survival of ovarian
cancer patients (Shah et al., 2014).
1.2 Functional Assessment of TP53I3- S252*
1.2.1 Loss of TP53I3 or TP53I3-s252* significantly decreases homologous
recombination repair (HRR)
Many of the genes currently on the HBOC testing panel are involved in DNA
repair mechanisms. Ovarian and breast cancer panel genes such as ATM,
BRCA1, BRCA2, CHEK2, PALB2, RAD51D, and RAD50 have important roles in
the HRR mechanism. For repair of DSB with HRR, the ATM protein detects the
break and phosphorylates numerous proteins including Chk2 and BRCA1
(Maréchal & Zou, 2013). A key regulator of ATM activation is the MRN complex
which consisting of Mre11, Rad50 and Nbs1 (Maréchal & Zou, 2013; Symington,
2014). Rad51 interacts with BRCA1 and BRCA2 as well as PALB2 to replace RPA
and form filaments on the DNA. To determine how TP53I3 effects HRR, I used
HeLa-DR-GFP cells. The pDR-GFP plasmid contains two inactive green
fluorescent protein (GFP) allele, one has the SCE-1 endonuclease recognition site
and the other is truncated. Upon transfecting HeLa-DR-GFP cells with pCBASce1,
a DSB occurs and the truncated allele serves as a template for HRR of the lesion
and activation of GFP (Pierce, Johnson, Thompson, & Jasin, 1999b). This assay
was employed to determine whether loss of TP53AIP1, TP53I3, and TP53I3-S252*
mutation effects HRR (Figure 12). Because BRCA1 is well established to have a
primary role in the HRR mechanism, it is expected that knockdown of the
endogenous protein will result in a significant reduction in HRR. Therefore, the
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BRCA1 siRNA knockdown condition was used as a concurrent control for the
transient co-transfections of the siRNA-test gene and the pCBASCE1 plasmid.
Overall, knockdown of TP53I3 significantly reduced by an average of 20% (p-value
≤ 0.05) HRR.

Attempting to rescue wildtype TP53I3 after knockdown was

successful, similar experiments with TP53I3-S252* also succeeds, but to a lesser
extent, indicating that the presence of the truncation negatively impacts its role in
HRR (p-value ≤ 0.05). Although the impact of TP53I3 (p-value ≤ 0.05) on HRR was
not as significant as panel gene BRCA1 (p-value ≤0.001), it has a similar effect to
other panel genes like CHEK2 and ATM (Lopes et al., 2019). The depletion of
TP53AIP1 with siRNA did not result in a significant reduction in HRR. This is
consistent with the primary function of the protein in p53-mediated apoptosis and
maintaining the mitochondrial membrane potential (Oda et al., 2000).
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A

B

C

Figure 12: TP53I3-S252* significantly defects Homologous Recombination
Repair
HeLa-DRGFP cells contain the p-DRGFP plasmid which has two inactive GFP
alleles. The SCE-1 endonuclease recognition side is located in the first allele and
the second allele is truncated. Introduction of pcBASce-1 to the cells causes a
double stranded break in the first GFP allele and the second GFP allele acts a
template for HRR of the lesion. Active GFP is a proxy for HRR having occurred in
the cell. (A) Effect of siRNA knockdown of BRCA1, TP53AIP1, TP53I3 or TP53I3
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with wildtype (TP53I3 WT) or mutant plasmid (TP53I3 S252*). (B) Fluorescent
imaging of HeLa-DRGFP cells repairing DSB (after pCBASce1 transfection) with
HRR compared to empty vector pCMV3. (C) Western blots for knockdown of
TP53I3, TP53I3 rescue with wildtype, TP53I3 rescue with mutant, BRCA1 and
TP53AIP1.
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1.2.2 TP53I3 deficient cells are sensitive to mitomycin C, bleomycin and
etoposide
Chemotherapy agents often given to HBOC patients were used, including
mitomycin c (MMC), bleomycin and etoposide. To determine how TP53I3 and
TP53I3-S252* affect drug response and cell death, the clonogenic assay was
employed. Because BRCA1 is a known HBOC panel gene, knockdown of the
protein with siRNA in HeLa-DRGFP cells was used to ensure siRNA transfection
could affect a drug response on cell survival. I determined the IC50 dosages to be
100 nM for mitomycin C (MMC), 1.5 µM for bleomycin and 4 µM for etoposide,
administered for four hours. In the absence of these cytotoxic agents knockdown
of BRCA1 and TP53I3 exhibited, respectively, 20% or 18% loss in the number of
viable clones (p-value ≤ 0.05) (Figure 13).
As expected BRCA1-deficient HeLa cells exhibited significant additional
sensitivity to MMC (p-value ≤ 0.001), bleomycin (p-value ≤ 0.001), and etoposide
(p-value ≤ 0.001). In the case of etoposide, there is an almost complete absence
of viable clones. Following a similar trend, loss of TP53I3 resulted in the cells
being significantly more sensitive (p-value ≤ 0.05) to all three drug treatments
(Figure 14). Approximately 60% of the cells survived after TP53I3 knockdown,
compared to the 80% in the scramble control (p-value ≤ 0.05). About 80% of cells
survived after knockdown of endogenous TP53I3 and rescue with the wildtype
plasmid. Similar to the scramble control. Knockdown of TP53I3 with siRNA and
attempted rescue with the TP53I3-S252* mutant plasmid resulted in a slight
increase in surviving cells, 82%, compared to the scramble control.
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A

B

Figure 13: TP53I3-S252* and TP53AIP1 reduces cell death
(A) Plating efficiency after knockdown of proteins and introduction of empty vector
(pCMV3), wildtype TP53I3 (TP53I3-WT), or S252* mutant (TP53I3-S252*). (B)
Representative qualitative images of each conditioned cell type.
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**p-value≤0.01
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Figure 14: TP53I3-S252* resistant to OVCA chemotherapy
(A) Surviving fraction after treatment with bleomycin, MMC or etoposide
incorporates plating efficiency. Representative images of surviving clones after
knockdown of protein of interest and introduction of empty vector (pCMV3),
wildtype TP53I3 (TP53I3-WT) or TP53I3 S252* mutant (TP53I3-S252*) after
bleomycin (B), MMC (C) or etoposide (C) treatment.
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1.2.3 TP53I3 S252* resistant to mitomycin C, bleomycin and etoposide
The depletion of endogenous TP53I3 and rescue with exogenous TP53I3S252* causes in a slight increase in the number of surviving clones compared to
the scrambled control (Figure 13). There was a significant increase in the number
of surviving clones after treatment with MMC (p-value ≤ 0.001) or etoposide (pvalue ≤ 0.001), displaying the resistance of the mutation to DNA damaging agents
(Figure 14A, C and D). This phenomenon could be explained by the mutant cells
multiplying and becoming more resistant to chemotherapy, gene amplification,
disruption of drug transportation across the cell wall, an alternative method of DNA
break repair or inactivation of the drug in the presence of the mutant. After
bleomycin treatment, an increase in the number of clones is observed but not
significantly.
1.2.4 TP53AIP1 response to mitomycin C, bleomycin and etoposide
The knockdown of TP53AIP1 did not significantly change the number of
surviving clones compared to scramble control (p-value = 0.595, Figure 13).
Similar to TP53I3-S252* cells, depleted TP53AIP1 HeLa-DRGFP cells were
resistant to mitomycin C (p-value ≤ 0.01) or etoposide treatment (p-value ≤ 0.01)
(Figure 14A, C and D). An opposite response was observed after bleomycin
treatment, with a significant decrease in surviving clones (p-value ≤ 0.05) (Figure
14A and B). Bleomycin is a radiomimetic drug that inhibits the synthesis of DNA,
indicating that a selective sensitivity to this drug by TP53AIP1 could provide a
targeted therapy option.
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1.2.5 TP53I3-S252* increases cell viability in the presence of oxidative stress
TP53I3-S252* may contribute to the resistance of chemotherapy often
given to HBOC patients. To further explore this finding, the clonogenic assay was
also utilized to determine how the mutation could affect cell death, due to TP53I3’s
role in ROS production and p53-mediated apoptosis. Hydrogen peroxide (H2O2)
has a well-defined role in apoptosis induction and ROS production by increasing
the formation of superoxide and hydroxyl radicals. Knockdown of TP53I3 in HeLa
cells followed by a four-hour H2O2 treatment (125 µM), did not change colony
formation compared to scramble control (Figure 15). However, in the presence of
TP53I3-S252* after endogenous TP53I3 knockdown and exposure to H 2O2, there
was a significant increase in colony formation (p-value ≤ 0.001). This suggests the
mutant disrupts a conversed region of the protein which, under wildtype conditions,
is involved in activating cell death. The mutant is adjacent to conserved residues
that make up the active binding site that interacts with QOR substrates for the
formation of ROS and resulting in eventual apoptosis (Porté et al., 2009). Under
conditions of TP53AIP1 knockdown and subsequent treatment, there was no
change in the number of surviving clones compared to the scramble control.
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***p-value ≤ 0.001
**p-value≤0.01
*p-value ≤ 0.05

B

Figure 15: TP53I3 - S252* response to oxidative stress
(A) Surviving fraction after treatment with H2O2 expressed in terms of plating
efficiency. (B) Representative qualitative images of each knockdown condition with
empty vector (pCMV3), wildtype TP53I3 (TP53I3-WT) or S252* mutant (TP53I3S252*).
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1.2.6 TP53I3-S252* decreases ROS production in the presence of H2O2 or
etoposide
The unique response of TP53I3-S252* in the clonogenic assay begs the
question of what mechanism is preventing cell death. TP53I3 has been described
as a member of the quinone oxidoreductase gene family that can catalyze the
formation of superoxide and hydroxyl ROS. The MitoSox probe allows for the
quantification of the induction of ROS bodies in the mitochondria. H2O2 and
etoposide had the most prominent effect on cell proliferation in the presence of
TP53I3-S252*. Also, both superoxide producing H2O2 and topoisomerase II
inhibitor etoposide have a well-defined role in ROS production (Wu & Yotnda,
2011). The response to etoposide was of particular interest because of it is
frequently employed in the treatment of a many cancers, including those seen in
HBOC high-risk subjects. HeLa cells depleted of TP53I3 or TP53AIP1 significantly
increased the production of ROS after exposure to H2O2 (p-value ≤ 0.05, Figure
16). In contrast, there was a decrease in ROS production in the presence of
TP53I3-S252* and treatment with H2O2 (p-value ≤ 0.05) or etoposide (p-value ≤
0.05, Figure 16). This is likely due to the fact that the truncation interrupts 3
downstream nucleotides that are conserved and part of the active binding site that
is needed form ROS in the presence of ortho-quinone (Porté et al., 2009)
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Figure 16: TP53I3-S252* disrupts mitochondrial ROS production
Proteins of interest were knockdown in HeLa cells (without DR-GFP) and/or
rescued with TP53I3 wildtype or TP53I3-S252* followed by treatment with H2O2 or
etoposide.

82
CHAPTER 4 – DISCUSSION
1.1 Whole exome sequencing is a more powerful tool for genetic risk
assessment than a traditional candidate gene approach
Whole exome sequencing provides an enriched data set to identify disease
risk loci. In the past decade, there has been an influx of larger and more inclusive
gene panels, but the issue of low diagnostic yield and missing heritability remains
(Chaudhry et al., 2017). As genetic panels are being continuously updated and
with a rapid decrease in the cost of WES/WGS it would be beneficial to take a NGS
approach to identify an individual’s true genetic risk. This study has been able to
demonstrate the benefits of utilizing WES data of high-risk hereditary breast and
ovarian cancer patients. Variant assessment of WES resulted in the identification
of clinically actionable mutations and post hoc assessment of candidate risk loci in
DNA repair and cell cycle regulation. In addition, the findings in this thesis implicate
apoptosis genes and the apoptosis pathway as a whole to be important in
addressing the issue of missing heritability in HBOC.
Traditionally, patients undergo genetic panel testing involving high
throughput sequencing of target genes. When using WES all genes on a panel test
can be assessed and the data can be mined any time in the future when additional
novel risk loci are identified. We found five clinically actionable genetic variants
(Lopes et al., 2019; Stafford et al., 2017) in our cohort of 48 HBOC patients. An
exciting finding among them was the FANCM R1931*(rs144567652) nonsense
mutation. The FANCM gene is not on any cancer genetic panel, but there is a
consensus amongst clinicians and researchers that it soon will be. FANCM is
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specifically involved in the recognition of interstrand cross-links (ICL) and recruits
BRCA1 for downstream DNA repair by HRR (Whitby, 2010; Xue, Sung, & Zhao,
2015). Additionally, consistent with our findings (Chaudhry et al., 2017; Lopes et
al., 2019; Stafford et al., 2017) the rs144567652 variant was found to increase the
risk of triple-negative breast cancer (Figlioli et al., 2019; Peterlongo et al., 2015)
and hereditary ovarian cancer (Dicks et al., 2017).
1.2 The necessity to assess cell death pathway genes for genetic risk
assessment of cancer
From our OVCA cohort, there was an enrichment of rare, high impact
mutations in apoptosis genes. Many of these truncated genes already have an
association with a variety of cancers. Two unrelated OVCA patients carry either
the rs141395772 or rs140191758 truncation in TP53AIP1. Both these SNPs have
been previously associated with melanoma (Benfodda et al., 2018) and could be
considered VUSs due to opposing reports on the effect of the mutations on
prostate cancer (Luedeke et al., 2012b). There was an overrepresentation of
truncations in BCL2 in our cohort, with four of the patients carrying rs140096922
or rs61731960. Given BCL2’s prominent role in the regulation of apoptosis and
mitochondrial membrane potential, defects in its protein function can have
detrimental defects to a variety of programmed cell death and DNA repair
mechanisms. A total of 18 patients carried a truncated apoptosis gene, as well as
the patients carrying 11 high impact DNA repair truncations. Apoptosis is a tightly
controlled and conserved mechanism, and therefore programmed cell death
pathways should not be overlooked when examining hereditary cancer risk.
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1.3 TP53I3 has an important role in DNA damage and apoptosis
Two of the HBOC patients carry a rare, premature stop gain mutations
S252* in TP53I3. Based on overexpression, knockdown or allele frequency,this
gene has been associated with squamous cell carcinoma of the breast (Gorgoulis
et al., 2004), squamous cell carcinoma of the head and neck (Guan et al., 2013),
myeloid leukemia (Nomdedéu et al., 2004), lung (Gorgoulis et al., 2004) and
invasive bladder (Ito et al., 2006). However, there has yet to be an example of
germline mutational changes in TP53I3 associated with disease risk in cancer
patients. The gene is important to mechanisms associated with maintaining the
integrity of DNA and cellular homeostasis. The mechanisms include TP53I3 being
transcriptionally regulated by TP53 (A Kotsinas et al., 2010) for response to DNA
damage (Lee et al., 2010) and apoptosis (Flatt et al., 2000). TP53I3 is a quinone
oxidoreductase involved in redox reaction to continuously produce ROS, vital to
maintaining cellular homeostasis (Bolton & Dunlap, 2017; Oppermann, 2007;
Porté et al., 2009). Therefore, mutations genes involved in the pathways can have
detrimental consequences for cells to properly function (Jeggo, Pearl, & Carr,
2016). TP53I3 is considered to be an upstream regulator of the DDR pathway,
which, unlikeTP53, are rarely altered. So the potential of a positive feedback loop
of TP53I3 being p53 transcriptionally activated and its role DDR will likely not be
compromised because mutated p53 is enough to effect repair and cell death
mechanisms. In short, loss of TP53I3 would have a negative impact on both normal
and cancer cells (Athanassios Kotsinas et al., 2012). Therefore, mutations in this
gene should be significant, whether they are truncations or missense mutations.
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The TP53I3-S252* mutation is in the fourth exon and in its presence, the
cells did not rescue DDR, demonstrated a decrease in ROS production, and a
resistance to cell death in the presence of cytotoxic agents. The PIG3AS is a splice
variant for TP53I3 in which exon 4 is spliced out, resulting in an inactive protein. A
functional consequence of when the splice variant is preferentially translated is the
disruption of ROS formation. This is due to the absence of the C-terminus
sequence, which is homologous with a QOR a subclass of the MDR superfamily
(Nicholls et al., 2004). Additionally, the missense mutation of serine at position 151
to valine in the protein disrupts a conserved binding motif for NADP+
(A/G)XXSXXG (Edwards et al., 1996). This makes the protein enzymatically
inactive because of steric hindrance and not allowing NADP+ to bind. In the
presence of substrate quinone 1,2-NQ and cofactor NADPH, there was a decrease
in binding affinity to the enzyme resulting in a loss of ROS production (Porté et al.,
2009). The presence of the TP53I3-S252* mutation at the fourth exon resulted in
a truncation due to a nonsense mutation. There are two possible explanations as
to why the mutant exhibits opposing phenotypes of ROS production and cell death
when comparing scramble siRNA to TP53I3 siRNA knockdown. Either there was
a loss of the enzymatic ability to the TP53I3 due to the truncation or the mutation
has a dominant negative effect that changes ROS production and cell death.
The location of the nonsense mutation is in position 252 of the TP53I3
protein sequence, where serine is altered to a premature stop codon. At the very
least, this nonsense mutation found in TP53I3 shortens the protein and it is
nonfunctional. Due to the position of the truncation, this could be an issue for the
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enzymatic ability of the protein. Recall that the residues involved in the active site
include Leu255, Phe256, and Leu265 (Porté et al., 2009). TP53I3 is disrupted by
a nonsense mutation found in two of the OVCA patients which prevents the
translation of the mRNA sequence after position 252. This means that three of the
15 residues necessary for the enzymatic activity of TP53I3 are not present. This
likely affects the active site conformation, preventing quinone substrates like 1,2NQ from binding efficiently, if at all. Also, the ability to reduce free molecular
oxygen to produce ROS species in the presence of a cofactor is severely
diminished. This is supported by the fact that TP53I3-S252* cells had a significant
decrease in mitochondrial ROS production in the form of H2O2, which can be
reduced to hydroxyl radicals (Figure 16). Furthermore, I observed that in the
presence of H2O2 the TP53I3-S252* cells experienced less cell death than wildtype
TP53I3 (Figure 15). After the administration of chemotherapy drugs bleomycin,
MMC or etoposide there was also a resistance to cell death in the TP53I3-S252*
mutant cells compared to the scramble control (Figure 14). In the case of MMC
and etoposide, there was a significant increase in the number of surviving cells in
the presence of the nonsense mutation in TP53I3. To maintain normal cellular
homeostasis, high levels of cellular ROS should lead to the activation of
programmed cell death such as apoptosis. The inability to regulate apoptosis can
result in the accumulation of old and damaged cells, which will could lead to
tumorigenesis.
An alternative hypothesis could be that a dominant negative phenotype is
observed in the presence of the TP53I3-S252* mutant. A dominant negative
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phenotype is when the mutant outcompetes the wildtype. The dominant negative
observed by the mutant in the presence of MMC, etoposide or H2O2 could be due
to the disruption in the area of the protein responsible for oxidoreductase of
superoxide ROS (Figure 14 and 15). This is further suggested by the reduction
of mitochondrial superoxide ROS after H2O2 treatment in the presence of TP53I3S252* (Figure 16). A particular surprising observation is an increase in ROS
production after TP53I3 knockdown. The TP53I3 siRNA targets the 3’UTR, which
is outside of the region that is homologous with the MDR superfamily. Since siRNA
knockdown is not a complete knockout of protein function and there is no disruption
of the residues involved in the conformation of the active site, the TP53I3 siRNA
would therefore not hinder the effects of cells undergoing ROS production (Figure
16) and eventual cell death (Figure 14 and 15). The opposing effects on cell death
and oxidative stress when comparing TP53I3 knockdown cells to TP53I3-S252*
cells depletion of TP53I3 and TP53I3-S252* suggests a dominant negative pattern.
Tumor suppressor genes p53 (Willis, Jung, Wakefield, & Chen, 2004) and BRCA1
(Thangaraju, Kaufmann, & Couch, 2000) and ATM (Chenevix-Trench, 2002)
genes are known to have dominant-negative mutations that result in carcinomas.
However, due to the fact that TP53I3-S252* mutation is positioned adjacent to
three amino acid residues necessary for the integrity and confirmation of the active
binding site of quinone substrates, it is more likely that mutation is affecting
enzymatic activity of the protein.
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Chapter 5 – LIMITATIONS AND FUTURE DIRECTIONS

This study extended the scope of our previously published work to examine
apoptosis associated genes role in cancer risk. A larger set of missense mutations
in apoptosis associated genes were also identified and passed the computational
filters applied including low MAF, high read quality, annotated as deleterious or
possibly deleterious by Polyphen, Sift or SnpEff and found in clinical databases
ClinVar, ACMG, COSMIC, TCGA, SNPEff. This is a dataset that can answer
questions about polygenetic effect where there are multiple medium or low impact
mutations observed in cancer patients. Additionally, pathway analysis of the HBOC
patients against a normal population from a database such as 1000genome or
TCGA would also shed light on other mechanisms that are often overlooked.
While the second portion of this project focused on the functional
assessment of TP53I3-S252* mutation, there were several other high impact
mutations found in apoptosis genes. Some of the mutations were found in multiple
patients like those in TP53AIP1, BCLAF1, and PIK3C2G. These genes are
involved in programmed cell death. To determine the effect of the truncations found
in the OVCA patients, similar experiments to those used for TP53I3-S252* can be
used. This would include, the clonogenic assay using DNA damaging and
apoptosis cytotoxic agents, the Annexin V assay, and mitochondrial membrane
potential-dependent assay.

To further support the hypothesis that TP53I3-S252* is enzymatically
inactive, kinetic analysis of the mutant in the presence of a QOR like 1,2-NQ with
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cofactor NADPH would be required. Comparing the effect of the truncation at
amino acid to the known inactivating TP53I3-S151V would also be beneficial and
to determine if the deficiency in substrate binding is similar. Testing to see how
both intercellular and mitochondrial ROS is affected by both mutants will also help
assess the severity of the nonsense truncation on oxidative stress response and
downstream apoptosis. To directly determine the effect of TP53I3-S252* on
apoptosis, the Annexin V assay can be utilized in the presence of similar cytotoxic
drugs used in this study. It would be important to include a drug that is considered
a positive control for apoptosis, such as camptothecin (CPT). CPT leads disrupts
mitochondrial membrane potential, resulting in the release of cytochrome c
release, caspase-3 activation, and ROS formation. TP53I3-S252* and TP53I3S151V expressing TP53I3 knockout cell lines would also be advantageous for the
above mentioned experiments to determine the heterozygote and homozygote
effects of both mutants.
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A quarter of all cases of ovarian cancer (OVCA) cases are associated with
inherited risk. However, due to unclassified variants or variants of unknown
significance (VUS), much of an individual hereditary risk remains unknown. We
have established the importance of whole exome sequencing to answer the
question of missing heritability. Five clinically actionable and eleven novel risk loci
in the DNA repair and cell cycle regulation pathways were identified by in silico
SNP assessment of a cohort of women diagnosed with OVCA, wildtype for
BRCA1/BRCA2 and suspected to be hereditary due to family history of breast
cancer/OVCA. Equally as important was the exploration and discovery of novel
risk loci in the apoptosis pathway. A total of thirteen truncating mutations in
apoptosis genes were found in over 35% of our patient cohort. The TP53I3-S252*
premature stop gain was identified in two unrelated patients, one of whom also
carries the clinically actionable truncating variant in FANCM. The proposed
function of TP53I3 is its ability to maintain DNA damage response and is
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transcriptionally activated by p53 to cause ROS induced apoptosis. It has been
hypothesized to be a key gene that connects DNA repair mechanisms with
downstream apoptosis as a quinone oxidoreductase. Additionally, two truncations
in TP53AIP1, two in BCLAF1 and one in PIK3C2G were identified in multiple
individuals. This study highlights the importance of the often overlooked pathway
of apoptosis. The importance of genetic assessment of the apoptosis pathway was
further strengthened back the observation that TP53I3-S252* significantly
decreases homologous recombination repair (HRR) and significantly resists
response to chemotherapy drugs bleomycin, mitomycin c (MMC) and etoposide.
Additionally, in the presence of oxidative stress from hydrogen peroxide and/or
etoposide there was a reduction in the formation of reactive oxygen species, which
is an important precursor to apoptosis. Lastly, the combination of computational
and bench lab techniques allows for a streamlined assessment of an individual’s
true genetic risk of disease.
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